Mission
We provide rigorous, transparent financial modeling tools for early-stage biotech asset valuation. The platform combines peer-reviewed clinical success rate data with industry-standard risk-adjusted NPV methodology, making institutional-quality pipeline valuation accessible to anyone making a real go/no-go decision — founders running diligence on their own assets, investors evaluating a candidate investment, and tech transfer offices pricing a license.
Every assumption is traceable. Every benchmark is sourced. Every calculation is documented in our methodology.
Team
Tamal Adebisi
Founder & Developer
Building PhaseFolio to bridge the gap between biotech science and financial modeling. Responsible for platform architecture, computational engine development, and clinical data pipeline design.
Model Governance
Financial models are only as trustworthy as the process behind them. PhaseFolio follows a structured approach to maintaining data quality and computational integrity.
All probability-of-success benchmarks derive from peer-reviewed, published sources. The primary dataset is the BIO/QLS/Informa Clinical Development Success Rates study (2011–2020), supplemented by indication-specific data from Nature, ASCO, and the Tufts Center for the Study of Drug Development.
Multiplier adjustments (genetic validation, orphan designation, biomarker strategy, mechanism novelty) are implemented as odds ratios using logistic transformation, preserving the [0,1] probability bound. Sources and derivations are documented in Section 1.2 of the methodology.
The rNPV engine is validated against published academic benchmarks. Phase-transition rates are cross-referenced with BIO/QLS 2021, Wong et al. 2019, and Sun et al. 2025. Monte Carlo simulations use sequential Bernoulli (rpNPV) sampling as recommended by Walker & Newell (2015), with Gaussian copula correlation for cost-duration uncertainty.
Backend computation is covered by automated tests that verify output consistency against known analytical solutions and published reference values.
Benchmark data is updated when new peer-reviewed studies are published. The CT.gov and FDA data pipelines provide supplementary real-world evidence for phase-transition validation. All updates are versioned and documented.
Current methodology version: 1.0 (April 2026). See the full methodology for the complete specification.
Data & Privacy
PhaseFolio processes financial projections that may be commercially sensitive. All project data is scoped by organization, encrypted in transit (TLS 1.3), and stored in a PostgreSQL database with row-level security. Authentication is managed by Clerk with organization-based JWT tokens.
We do not sell, share, or use customer data to train models. Benchmark data is derived exclusively from publicly available, peer-reviewed clinical trial databases and regulatory filings.
Contact
For methodology questions, partnership inquiries, or feedback, reach us at contact@phasefolio.com.
PhaseFolio is currently in beta. We actively incorporate user feedback into platform development.
PhaseFolio
© 2026 PhaseFolio. All rights reserved.